GLPwatch
Papers (9189)
Page 52 of 154, ranked by citation count.
- Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
- A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.
- Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway.
- Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
- Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
- Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.
- Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.
- Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
- The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.
- Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.
- Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
- Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
- Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.
- Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
- Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.
- Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome.
- Clinical review of subcutaneous semaglutide for obesity.
- Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility.
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data.
- The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
- Liraglutide-induced autoimmune hepatitis.
- Effects of liraglutide among patients living with psoriasis and obesity.
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
- Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
- A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
- GLP-1R agonists for the treatment of obesity: a patent review (2015-present).
- Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
- Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway.
- Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
- The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV.
- Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.
- Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.
- Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes.
- The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
- Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway.
- Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.
- The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
- Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.
- Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.
- Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study.
- Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.
- Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.
- Liraglutide reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells.
- Once weekly exenatide: efficacy, tolerability and place in therapy.
- Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
- Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
- PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury.
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
- Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy.
- Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.
- Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
- Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
- Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
- Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.
- Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice.
- Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
- Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial.
- Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
- Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.